Moderna (MRNA) fell 12.8% to $82.68 on Monday after J.P. Morgan analyst Cory Kasimov downgraded the stock to neutral from buy citing the company’s high valuation. However, he increased the price target to $89 from $60.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Moderna’s solid bull-run on expectations of the development of a potential COVID-19 vaccine has driven its stock up about 323% this year. It is up over 488% year-on-year.
The analyst stated that he remains bullish on the long-term prospects of the company and considers it to be a frontrunner to bring out a COVID-19 vaccine. However, given the significant growth in its stock and uncertainty surrounding the COVID-19 vaccine, including its price, duration, and competition, its valuation seems unjustified.
On July 15, Oppenheimer analyst Hartaj Singh reiterated his buy rating on the stock with a price target of $108. Overall MRNA shows a Strong Buy Street consensus, with 13 analysts suggesting a buy and 3 analysts recommending a hold. The average analyst price target stands at $93.79, implying a 13.4% upside potential. (See Moderna’s stock analysis on TipRanks).
Related News:
NuVasive Spikes 5% After-Hours On Sharp Procedure Rebound
Acadia Plunges 12% As Depressive Study Misses Goals; Analyst Says Buy
Is Novavax’s (NVAX) Super-High Valuation Justified? This Analyst Says ‘Yes’
